IgGenix, Inc., a clinical-stage biotechnology company pioneering innovative treatments for immune-mediated diseases, today ...

The LNP-mRNA modality is a novel approach that uses lipid nanoparticles to deliver messenger RNA into cells. The mRNA acts as ...

CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, /PRNewswire/ -- Harbour BioMed (HKEX: 02142, the 'Company'), a global ...

Cambridge, Massachusetts Thursday, February 6, 2025, 13:00 Hrs [IST] ...

Mozart Therapeutics, the leading developer of CD8 Treg network modulators in autoimmune disease, announces the presentation ...

Based on continued emergence of bempikibart data from SIGNAL-AA Part A, including strong re-consent rates and patient demand for continued dosing, Company initiating ...

It is closely associated with tumorigenesis and drug resistance, making it a potential target for oncology drug development. To date, no ROR1-targeting drugs have been marketed. BR111 utilizes ...

Omeros Corporation (Nasdaq: OMER) today announced two presentations that will be featured at the 2025 Tandem Meetings – the ...

Regeneron UK Limited today announced that the Scottish Medicines Consortium (SMC) has accepted Libtayo® (cemiplimab) for use on the National Health Service as a second-line monotherapy treatment for ...

Indaptus Therapeutics, Inc. (Nasdaq: INDP) (“Indaptus” or the “Company”), a clinical-stage biotechnology company pioneering innovative cancer and viral infection treatments, today announced the ...

Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that a detailed analysis of its phase III REGENCY trial of Gazyva®/Gazyvaro® (obinutuzumab) in people with active lupus nephritis (LN) was published ...

Company plans to initiate a Phase 1/b trial in relapsed/refractory, locally advanced/metastatic bladder cancer by year-end ...